Back to Search

A Phase 2, Randomized, Open-label Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients With a KRAS or NRAS Mutation

  • Protocol Number: 202301003
  • Principal Investigator: Pedersen, Katrina
  • Cancer Types: Gastrointestinal

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions